Download PDF
Dtsch Med Wochenschr 2001; 126(21): 625-627
DOI: 10.1055/s-2001-14417
Der Arzneistoff
© Georg Thieme Verlag Stuttgart · New York

Amiodaron

Amiodarone
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

Amiodaron wurde ursprünglich in den 60er Jahren als Pharmakon zur Therapie der Angina pectoris eingeführt. Erst später wurden die antiarrhythmischen Eigenschaften von Amiodaron erkannt [1-3].

Literatur

  • 1 Charlier R. Récherches dans la séries des benzfurannes. VII. Etude pharmacologique préliminaire du butyl-2(diiodo-3’,5’-B-N-diethylaminoethoxy-4’ benzoyl)-3 benzfuranne.  Arch Int Pharmacodyn. 1962;  139 255-262
    Google Scholar
  • 2 Singh B N. Amiodarone: historical development and pharmacologic profile.  Am Heart J. 1983;  106 788-797
    Google Scholar
  • 3 Vastesaeger M. Etude clinique d’une nouvelle médication antiangoreuse.  Acta Cardiol (Brux). 1964;  22 483
    Google Scholar
  • 4 Lai L P, Su M J, Tseng Y Z, Lien W P. Sensitivity of the slow component of the delayed rectifier potassium current (IKs) to potassium channel blockers: Implications for clinical reverse use-dependent effects.  J Biomed Sci. 1999;  6 251-259
    Google Scholar
  • 5 Sanguinetti M C, Jurkiewicz N K. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.  J Gen Physiol. 1990;  96 195-215
    Google Scholar
  • 6 Julian D G, Camm A J, Frangin G, Janse M J, Munoz A, Schwartz P J, Simon P. Investigators: EMIAT. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT.  Lancet. 1997;  349 667-674
    Google Scholar
  • 7 Amiodarone Trials Meta-analysis Investigators . The effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual patient data on 6500 patients from randomized trials.  Lancet. 1997;  350 1417-1424
    Google Scholar
  • 8 Hohnloser S H, Klingenheben T, Singh B N. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia.  Ann Intern Med. 1994;  121 529-535
    Google Scholar
  • 9 Cairns J A, Connolly S J, Roberts R S, Gent M, Investigators T C. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT.  Lancet. 1997;  349 675-682
    Google Scholar
  • 10 Yin Y L, Perret G Y, Nicolas P, Vassy R, Uzzan B, Tod M. In vivo effects of amiodarone on cardiac beta-adrenoceptor density and heart rate require thyroid hormones.  J Cardiovasc Pharmacol. 1992;  19 541-545
    Google Scholar
  • 11 Latham K R, Sellitti D F, Goldstein R E. Interaction of amiodarone and desethylamiodarone with solubilized nuclear thyroid hormone receptors.  J Am Coll Cardiol. 1987;  9 872-876
    Google Scholar
  • 12 Drvota V, Blange I, Haggblad J, Sylven C. Desethylamiodarone prolongation of cardiac repolarization is dependent on gene expression: a novel antiarrhythmic mechanism.  J Cardiovasc Pharmacol. 1998;  32 654-661
    Google Scholar
  • 13 van Beeren H C, Bakker O, Wiersinga W M. Structure-function relationship of the inhibition of the 3,5,3’-triiodothyronine binding to the alpha1- and beta1-thyroid hormone receptor by amiodarone analogs.  Endocrinology. 1996;  137 2807-2814
    Google Scholar
  • 14 Aanderaud S, Sundsfjord J, Aarbokke J. Amiodarone inhibits the conversion of thyroxin to triiodothyronine inisolated rat heaptocytes.  Endocrinology. 1984;  115 1605-1608
    Google Scholar
  • 15 Krenning E P, Docter R, Bernard B, Visser T, Hennemann G. Decreased transport of thyroxine (T4), 3,3’,5-triiodothyronine (T3) and 3,3’,5’-triiodothyronine (rT3) into rat hepatocytes in primary culture due to a decrease of cellular ATP content and various drugs.  FEBS Lett. 1982;  140 229-233
    Google Scholar
  • 16 Connolly S J. Meta-analysis of antiarrhythmic drug trials.  Am J Cardiol. 1999;  84 90R-93R
    Google Scholar
  • 17 Connolly S J. Evidence-based analysis of amiodarone efficacy and safety.  Circulation. 1999;  100 2025-2034
    Google Scholar
  • 18 Herbette L G, Trumbore M, Chester D W, Katz A M. Possible molecular basis for the pharmacokinetics and pharmacodynamics of three membrane-active drugs: propranolol, nimodipine and amiodarone.  J Mol Cell Cardiol. 1988;  20 373-378
    Google Scholar
  • 19 Hein L, Lüllmann-Rauch R, Mohr K. Human accumulation potential of xenobiotics: potential of catamphiphilic drugs to promote their accumulation via inducing lipidosis or mucopolysaccharidosis.  Xenobiotica. 1990;  20 1259-1267
    Google Scholar
  • 20 Holt D W, Tucker G T, Jackson P R, Storey G CA. Amiodarone pharmacokinetics.  Am Heart J. 1983;  106 840-847
    Google Scholar
  • 21 Adams P C, Holt D W, Storey G CA, Morley A R, Callaghan J, Path M RC, Campbell R WF. Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy.  Ther Prev Pharmacol. 1985;  72 1064-1075
    Google Scholar
  • 22 Pollak P T, Bouillon T, Shafer S L. Population pharmacokinetics of long-term oral amiodarone therapy.  Clin Pharmacol Ther. 2000;  67 642-652
    Google Scholar
  • 23 Mason J W. Amiodarone.  N Engl J Med. 1987;  316 455-466
    Google Scholar
  • 24 Francois J. Cornea verticillata.  Bull Soc Belge Ophthalmol. 1968;  150 656-670
    Google Scholar
  • 25 D’Amico D J, Kenyon K R, Ruskin J N. Amiodarone keratopathy: drug-induced lipid storage disease.  Arch Ophthalmol. 1981;  99 257-261
    Google Scholar
  • 26 Pollak P T. Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations.  Am J Cardiol. 1999;  84 37R-45R
    Google Scholar
  • 27 Vorperian V R, Havighurst T C, Miller S, January C T. Adverse effects of low dose amiodarone: a meta-analysis.  J Am Coll Cardiol. 1997;  30 791-798
    Google Scholar
  • 28 Loh K C. Amiodarone-induced thyroid disorders: A clinical review.  Postgrad Med J. 2000;  76 133-140
    Google Scholar
  • 29 Hennersdorf M G, Strauer B E. Herzrhythmusstörungen bei Hyperthyreose.  Dtsch Med Wschr. 2000;  125 637-641
    Google Scholar

Korrespondenz

PD Dr. med. Lutz Hein

Institut für Pharmakologie Universität Würzburg

Versbacher Strasse 9

97078 Würzburg

Phone: 0931/2013435

Fax: 0931/2013539

Email: hein@toxi.uni-wuerzburg.de